Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Cancer Cell International
Published in: Cancer Cell International 1/2020

01-12-2020 | Colorectal Cancer | Primary research

MicroRNA-138-5p targets the NFIB-Snail1 axis to inhibit colorectal cancer cell migration and chemoresistance

Authors: Weifeng Xu, Beibei Chen, Dianshan Ke, Xiaobing Chen

Published in: Cancer Cell International | Issue 1/2020

Login to get access

Abstract

Background

Colorectal cancer ranks among the most lethal diseases worldwide. Although much progress has been made in research and treatment of colorectal cancer in recent years, the underlying mechanisms related to migration of the cancer cells and the reason for chemoresistance still remain unclear. In this research, we explored the underlying effect of miR-138-5p in colorectal cancer.

Methods

We used qRT-PCR to investigate the expression of miR-138-5p, Snail1, NFIB in colorectal cancer cells. Lentiviral vectors containing miR-138-5p mimics and inhibitors were constructed and transfected cells. Wound healing assay was applied to illustrate interferences on cell migration. Fluorouracial, doxorubicin, cisplat in were used to detect chemotherapy resistance. In order to identify target genes, bioinformatic methods were applied. Snail1 and NFIB protein expression in stable cell lines was detected using Western blot. Double luciferase and CHIP experiment were used to verify binding sites. We used rescue experiments to further explore the interactions among Snail1, NFIB and miR-138-5p.

Results

The expression of miR-138-5p in colorectal cancer cells was low. miR-138-5p inhibited cell migration in colorectal cancer, and could negatively regulate chemotherapy resistance. miR-138-5p targeted NFIB, and regulated Snail1 expression, which mediated colorectal cancer cell migration and chemotherapy resistance.

Conclusions

Our research indicates that miR-138-5p could be a crucial modulator controlling colorectal cancer cell migration and chemoresistance, by acting upon the NFIB-Snail1 axis. miR-138-5p has an emerging prospect to be exploited as a new target for colorectal cancer.
Literature
1.
2.
Siegel RL, Miller KD, Goding Sauer A, Fedewa SA, Butterly LF, Anderson JC, Cercek A, Smith RA, Jemal A. Colorectal cancer statistics, 2020. CA Cancer J Clin. 2020;70(3):145–64.CrossRefPubMed
3.
Brown KGM, Solomon MJ, Mahon K, O’Shannassy S. Management of colorectal cancer. BMJ. 2019;366:l4561.CrossRefPubMed
4.
Keller DS, Berho M, Perez RO, Wexner SD, Chand M. The multidisciplinary management of rectal cancer. Nat Rev Gastroenterol Hepatol. 2020;17(7):414–29.CrossRefPubMed
5.
Yang J, Yang XS, Zhang Q, Zhuang X, Dong XK, Jiang YH, Tao YN, Yang CH. Downregulated LINC01614 ameliorates hypoxia/reoxygenation-stimulated myocardial injury by directly sponging microRNA-138-5p. Dose Response. 2020;18(1):1559325820913786.PubMedPubMedCentral
6.
Deng Y, Chen D, Gao F, Lv H, Zhang G, Sun X, Liu L, Mo D, Ma N, Song L, et al. Exosomes derived from microRNA-138-5p-overexpressing bone marrow-derived mesenchymal stem cells confer neuroprotection to astrocytes following ischemic stroke via inhibition of LCN2. J Biol Eng. 2019;13:71.CrossRefPubMedPubMedCentral
7.
Yu C, Wang M, Li Z, Xiao J, Peng F, Guo X, Deng Y, Jiang J, Sun C. MicroRNA-138-5p regulates pancreatic cancer cell growth through targeting FOXC1. Cell Oncol. 2015;38(3):173–81.CrossRef
8.
Yu C, Wang M, Chen M, Huang Y, Jiang J. Upregulation of microRNA1385p inhibits pancreatic cancer cell migration and increases chemotherapy sensitivity. Mol Med Rep. 2015;12(4):5135–40.CrossRefPubMed
9.
Gao W, Lam JW, Li JZ, Chen SQ, Tsang RK, Chan JY, Wong TS. MicroRNA-138-5p controls sensitivity of nasopharyngeal carcinoma to radiation by targeting EIF4EBP1. Oncol Rep. 2017;37(2):913–20.CrossRefPubMed
10.
Roberto GM, Lira RC, Delsin LE, Vieira GM, Silva MO, Hakime RG, Yamashita ME, Engel EE, Scrideli CA, Tone LG, et al. microRNA-138-5p as a worse prognosis biomarker in pediatric, adolescent, and young adult osteosarcoma. Pathol Oncol Res. 2020;26(2):877–83.CrossRefPubMed
11.
Zhao C, Ling X, Li X, Hou X, Zhao D. MicroRNA-138-5p inhibits cell migration, invasion and EMT in breast cancer by directly targeting RHBDD1. Breast Cancer. 2019;26(6):817–25.CrossRefPubMed
12.
Zhu D, Gu L, Li Z, Jin W, Lu Q, Ren T. MiR-138-5p suppresses lung adenocarcinoma cell epithelial-mesenchymal transition, proliferation and metastasis by targeting ZEB2. Pathol Res Pract. 2019;215(5):861–72.CrossRefPubMed
13.
Chen Y, Wang X. miRDB: an online database for prediction of functional microRNA targets. Nucleic Acids Res. 2020;48(D1):D127–31.CrossRefPubMed
14.
Vlachos IS, Vergoulis T, Paraskevopoulou MD, Lykokanellos F, Georgakilas G, Georgiou P, Chatzopoulos S, Karagkouni D, Christodoulou F, Dalamagas T, et al. DIANA-mirExTra v2.0: uncovering microRNAs and transcription factors with crucial roles in NGS expression data. Nucleic Acids Res. 2016;44(W1):W128–34.CrossRefPubMedPubMedCentral
15.
Mon-Lopez D, Tejero-Gonzalez CM. Validity and reliability of the TargetScan ISSF Pistol & Rifle application for measuring shooting performance. Scand J Med Sci Sports. 2019;29(11):1707–12.CrossRefPubMed
16.
Tang Z, Li C, Kang B, Gao G, Li C, Zhang Z. GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses. Nucleic Acids Res. 2017;45(W1):W98–102.CrossRefPubMedPubMedCentral
17.
Bromham N, Kallioinen M, Hoskin P, Davies RJ, Guideline C. Colorectal cancer: summary of NICE guidance. BMJ. 2020;368:m461.CrossRefPubMed
18.
Dekker E, Tanis PJ, Vleugels JLA, Kasi PM, Wallace MB. Colorectal cancer. Lancet. 2019;394(10207):1467–80.CrossRefPubMed
19.
Wang J, Li J, Yang J, Zhang L, Gao S, Jiao F, Yi M, Xu J. MicroRNA1385p regulates neural stem cell proliferation and differentiation in vitro by targeting TRIP6 expression. Mol Med Rep. 2017;16(5):7261–6.CrossRefPubMedPubMedCentral
20.
Weiss K, Treiber T, Meister G, Schratt G. The nuclear matrix protein Matr3 regulates processing of the synaptic microRNA-138-5p. Neurobiol Learn Mem. 2019;159:36–45.CrossRefPubMed
21.
Ma J, Zhang Y, Ji H, Chen L, Chen T, Guo C, Zhang S, Jia J, Niu P. Overexpression of miR-138-5p suppresses MnCl2 -induced autophagy by targeting SIRT1 in SH-SY5Y cells. Environ Toxicol. 2019;34(4):539–47.CrossRefPubMed
22.
Becker-Santos DD, Lonergan KM, Gronostajski RM, Lam WL. Nuclear Factor I/B: a master regulator of cell differentiation with paradoxical roles in cancer. EBioMedicine. 2017;22:2–9.CrossRefPubMedPubMedCentral
23.
24.
25.
Chen KS, Bridges CR, Lynton Z, Lim JWC, Stringer BW, Rajagopal R, Wong KT, Ganesan D, Ariffin H, Day BW, et al. Transcription factors NFIA and NFIB induce cellular differentiation in high-grade astrocytoma. J Neurooncol. 2020;146(1):41–53.CrossRefPubMed
26.
Wu C, Zhu X, Liu W, Ruan T, Wan W, Tao K. NFIB promotes cell growth, aggressiveness, metastasis and EMT of gastric cancer through the Akt/Stat3 signaling pathway. Oncol Rep. 2018;40(3):1565–73.PubMed
27.
Moon HG, Hwang KT, Kim JA, Kim HS, Lee MJ, Jung EM, Ko E, Han W, Noh DY. NFIB is a potential target for estrogen receptor-negative breast cancers. Mol Oncol. 2011;5(6):538–44.CrossRefPubMedPubMedCentral
28.
Liu RZ, Vo TM, Jain S, Choi WS, Garcia E, Monckton EA, Mackey JR, Godbout R. NFIB promotes cell survival by directly suppressing p21 transcription in TP53-mutated triple-negative breast cancer. J Pathol. 2019;247(2):186–98.CrossRefPubMed
29.
Liu Z, Chen J, Yuan W, Ruan H, Shu Y, Ji J, Wu L, Tang Q, Zhou Z, Zhang X, et al. Nuclear factor I/B promotes colorectal cancer cell proliferation, epithelial-mesenchymal transition and 5-fluorouracil resistance. Cancer Sci. 2019;110(1):86–98.CrossRefPubMed
30.
Wang Y, Yan T, Li J, Wang W, Wu Q, Shi J, Li D, Stovall DB, Zhang Q, Sui G. The SNAIL1 promoter contains G-quadruplex structures regulating its gene expression and DNA replication. Exp Cell Res. 2020;2020:112158.CrossRef
31.
32.
Herrera A, Herrera M, Pena C. The emerging role of Snail1 in the tumor stroma. Clin Transl Oncol. 2016;18(9):872–7.CrossRefPubMed
33.
Frey P, Devisme A, Schrempp M, Andrieux G, Boerries M, Hecht A. Canonical BMP signaling executes epithelial-mesenchymal transition downstream of SNAIL1. Cancers. 2020;12(4):1019.CrossRefPubMedCentral
34.
Maturi V, Moren A, Enroth S, Heldin CH, Moustakas A. Genomewide binding of transcription factor Snail1 in triple-negative breast cancer cells. Mol Oncol. 2018;12(7):1153–74.CrossRefPubMedPubMedCentral
35.
Brenot A, Knolhoff BL, DeNardo DG, Longmore GD. SNAIL1 action in tumor cells influences macrophage polarization and metastasis in breast cancer through altered GM-CSF secretion. Oncogenesis. 2018;7(3):32.CrossRefPubMedPubMedCentral
36.
Fendrich V, Jendryschek F, Beeck S, Albers M, Lauth M, Esni F, Heeger K, Dengler J, Slater EP, Holler JPN, et al. Genetic and pharmacologic abrogation of Snail1 inhibits acinar-to-ductal metaplasia in precursor lesions of pancreatic ductal adenocarcinoma and pancreatic injury. Oncogene. 2018;37(14):1845–56.CrossRefPubMed
37.
Zhang J, Hua X, Qi N, Han G, Yu J, Yu Y, Wei X, Li H, Chen X, Leng C, et al. MiR-27b suppresses epithelial-mesenchymal transition and chemoresistance in lung cancer by targeting Snail1. Life Sci. 2020;254:117238.CrossRefPubMed
38.
Li J, Qu J, Shi Y, Perfetto M, Ping Z, Christian L, Niu H, Mei S, Zhang Q, Yang X, et al. Nicotinic acid inhibits glioma invasion by facilitating Snail1 degradation. Sci Rep. 2017;7:43173.CrossRefPubMedPubMedCentral
39.
Yu S, Zhang Y, Li Q, Zhang Z, Zhao G, Xu J. CLDN6 promotes tumor progression through the YAP1-snail1 axis in gastric cancer. Cell Death Dis. 2019;10(12):949.CrossRefPubMedPubMedCentral
40.
Huang Z, Liang X, Wu W, Chen X, Zeng Q, Yang M, Ge J, Xia R. Mechanisms underlying the increased chemosensitivity of bortezomib-resistant multiple myeloma by silencing nuclear transcription factor Snail1. Oncol Rep. 2019;41(1):415–26.PubMed
41.
Maiques O, Barcelo C, Panosa A, Pijuan J, Orgaz JL, Rodriguez-Hernandez I, Matas-Nadal C, Tell G, Vilella R, Fabra A, et al. T-type calcium channels drive migration/invasion in BRAFV600E melanoma cells through Snail1. Pigment Cell Melanoma Res. 2018;31(4):484–95.CrossRefPubMed
42.
43.
Soucek K, Gajduskova P, Brazdova M, Hyzd’alova M, Koci L, Vydra D, Trojanec R, Pernicova Z, Lentvorska L, Hajduch M, et al. Fetal colon cell line FHC exhibits tumorigenic phenotype, complex karyotype, and TP53 gene mutation. Cancer Genet Cytogenet. 2010;197(2):107–16.CrossRefPubMed
Metadata
Title
MicroRNA-138-5p targets the NFIB-Snail1 axis to inhibit colorectal cancer cell migration and chemoresistance
Authors
Weifeng Xu
Beibei Chen
Dianshan Ke
Xiaobing Chen
Publication date
01-12-2020
Publisher
BioMed Central
Published in
Cancer Cell International / Issue 1/2020
Electronic ISSN: 1475-2867
DOI
https://doi.org/10.1186/s12935-020-01573-5

Other articles of this Issue 1/2020

Cancer Cell International 1/2020 Go to the issue

Primary research

The predictive value of lncRNA MIR31HG expression on clinical outcomes in patients with solid malignant tumors

Primary research

High CENPM mRNA expression and its prognostic significance in hepatocellular carcinoma: a study based on data mining

Primary research

CircRNA DONSON contributes to cisplatin resistance in gastric cancer cells by regulating miR-802/BMI1 axis

Primary research

Circular RNA circ-CSPP1 regulates CCNE2 to facilitate hepatocellular carcinoma cell growth via sponging miR-577

Primary research

SUV39H1-DNMT3A-mediated epigenetic regulation of Tim-3 and galectin-9 in the cervical cancer

Review

The emerging roles of non-coding competing endogenous RNA in hepatocellular carcinoma
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits